NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
about
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorA Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma.Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.The NF1 gene revisited - from bench to bedside.Targeted therapy in sarcomas other than GIST tumorsAkt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphomaEpigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-cateninImmunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.Modeling RASopathies with Genetically Modified Mouse Models.The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.Methods to generate genetically engineered mouse models of soft tissue sarcoma.Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formationImmune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome.NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.
P2860
Q27003534-67DA1F29-F987-45ED-92DC-4A2F7D8B637DQ30391185-099B3C51-4EB2-4CF6-9F8D-3B064A586A12Q33688908-13ABDDF9-BB53-4D4C-9C23-65D31E484661Q33737662-58F03A72-C9AA-4E46-8F14-A89F744A8691Q33899910-D65198F2-CF95-485E-9187-BB78109E34DFQ34227509-4E846DCA-B514-4CE8-9317-081EAD0EAC99Q35622367-9D2D6CEF-85C1-483D-9087-0836D5AEBF41Q35788976-238A1A2C-E8A5-4A52-BFC0-4879F7D02C69Q36100460-6CD82175-176B-419D-9D82-A13D70D71466Q36145645-AA422310-2E08-43D0-BACA-80D7D9B671BFQ37408543-F8897B43-F454-4992-BCAC-79B6BAA53ED0Q37619722-DB1440A6-9B69-46FB-8932-71E0A343D2E3Q38636749-5A2313DB-4817-4ACE-A969-B2E34EF1EC3EQ39030536-D71B2FEF-9B46-4EFA-AF32-0D313CE8EA13Q39031139-23DF52C2-5323-4BC9-882E-8F43DB425E52Q39045958-769ECDDC-2554-4086-B714-A0005C46E138Q41693158-A2D02914-22C9-47A2-B68C-4C343D2252F8Q42572216-F182836C-E31D-4504-9DB3-1DA59C36A0EBQ47144771-6B0C9257-7DA0-4920-A200-2B5CC159FAD2Q49830155-B1649F0A-4547-4A95-B375-319FDAC5263CQ51840300-53946260-C469-41AB-AAF8-0002EF6A7A86Q53478339-E73083EE-87EB-493F-93A7-1AFC1950C702Q54239575-F3E7B338-87C7-4213-B350-D880E26684BA
P2860
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
NF1 deletion generates multipl ...... hat respond to MEK inhibition.
@en
type
label
NF1 deletion generates multipl ...... hat respond to MEK inhibition.
@en
prefLabel
NF1 deletion generates multipl ...... hat respond to MEK inhibition.
@en
P2093
P2860
P1476
NF1 deletion generates multipl ...... that respond to MEK inhibition
@en
P2093
David G Kirsch
Jeffrey K Mito
Leslie Dodd
Mohit Sachdeva
Rebecca D Dodd
Rhea Chitalia
William C Eward
P2860
P304
P356
10.1158/1535-7163.MCT-13-0189
P577
2013-07-15T00:00:00Z